BRCA2 and neoplasm: Acquired chemotherapy resistance is mainly associated with the inactivation of tumour suppressors such as RB1, NF1, RAD51B and PTEN, germline BRCA1 or BRCA2 mutations, loss of BRCA1 promoter methylation, and overexpression of the drug efflux pump MDR12.